7,8-dihydroxyflavone ameliorates cognitive and motor deficits in a Huntington's disease mouse model through specific activation of the PLCγ1 pathway.

Hum Mol Genet 2017 08;26(16):3144-3160

Departament de Biomedicina, Facultat de Medicina, Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.

Huntington's disease (HD) is a fatal neurodegenerative disease with motor, cognitive and psychiatric impairment. Dysfunctions in HD models have been related to reduced levels of striatal brain-derived neurotrophic factor (BDNF) and imbalance between its receptors TrkB and p75(NTR). Thus, molecules with activity on the BDNF/TrkB/p75 system can have therapeutic potential. 7,8-Dihydroxyflavone (7,8-DHF) was described as a TrkB agonist in several models of neuro-degenerative diseases, however, its TrkB activation profile needs further investigation due to its pleiotropic properties and divergence from BDNF effect. To investigate this, we used in vitro and in vivo models of HD to dissect TrkB activation upon 7,8-DHF treatment. 7,8-DHF treatment in primary cultures showed phosphorylation of TrkBY816 but not TrkBY515 with activation of the PLCγ1 pathway leading to morphological and functional improvements. Chronic administration of 7,8-DHF delayed motor deficits in R6/1 mice and reversed deficits on the Novel Object Recognition Test (NORT) at 17 weeks. Morphological and biochemical analyses revealed improved striatal levels of enkephalin, and prevention of striatal volume loss. We found a TrkBY816 but not TrkBY515 phosphorylation recovery in striatum concordant with in vitro results. Additionally, 7,8-DHF normalized striatal levels of induced and neuronal nitric oxide synthase (iNOS and nNOS, respectively) and ameliorated the imbalance of p75/TrkB. Our results provide new insights into the mechanism of action of 7,8-DHF suggesting that its effect through the TrkB receptor in striatum is via selective phosphorylation of its Y816 residue and activation of PLCγ1 pathway, but pleiotropic effects of the drug also contribute to its therapeutic potential.

Download full-text PDF

Source
http://dx.doi.org/10.1093/hmg/ddx198DOI Listing
August 2017
30 Reads

Publication Analysis

Top Keywords

plcγ1 pathway
12
activation plcγ1
12
trkby816 trkby515
8
huntington's disease
8
trkb activation
8
therapeutic potential
8
motor deficits
8
striatal levels
8
78-dhf treatment
8
78-dhf
6
trkb
5
activation
5
striatum concordant
4
investigate vitro
4
concordant vitro
4
divergence bdnf
4
bdnf investigate
4
models dissect
4
phosphorylation recovery
4
treatment 78-dhf
4

References

(Supplied by CrossRef)
The Huntington’s Disease Collaborative Research Group
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes et al.
Cell 1993
Amino acid neurotransmitter abnormalities in Huntington’s disease and the quinolinic acid animal model of Huntington’s disease
Brain 1987
Potential therapeutic effects of neurotrophins for acute and chronic neurological diseases
Biomed. Res. Int 2014

Similar Publications